Drugs / MBF-015
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06049147 | Jul 2021 → Aug 2023 | — | Medibiofarma S.L. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06469853 | Feb → Dec 2024 | Huntington disease | Medibiofarma S.L. | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-03-11 | Medibiofarma S.L. | Medibiofarma S.L. announced the award of the European CommissionSeal of Excellence for their clinical asset MBF-015. medibiofarma.com ↗ |
| 2024-03-11 | Medibiofarma S.L. | First patient dosed in the Phase IIa clinical trial of MBF-015 in patients with Huntington’s disease medibiofarma.com ↗ |
| 2021-07-29 | Medibiofarma S.L. | MEDIBIOFARMA ANNOUNCES FIRST SUBJECT DOSED IN MBF-015 PHASE I CLINICAL STUDY: New HDAC1/2 inhibitor in healthy volunteers medibiofarma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MBF-015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06469853 ↗ |
| Action | Inhibit | “MBF-015 oral capsules Histone deacetylase inhibitor” NCT06049147 ↗ |
| Route | Oral | “MBF-015 will be administered as single oral ascending dose” NCT06049147 ↗ |